SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction

被引：22

作者：

Pissarnitski, DA ^{[1
]}

Asberom, T ^{[1
]}

Boyle, CD ^{[1
]}

Chackalamannil, S ^{[1
]}

Chintala, M ^{[1
]}

Clader, JW ^{[1
]}

Greenlee, WJ ^{[1
]}

Hu, YQ ^{[1
]}

Kurowski, S ^{[1
]}

Myers, J ^{[1
]}

Palamanda, J ^{[1
]}

Stamford, AW ^{[1
]}

Vemulapalli, S ^{[1
]}

Wang, YG ^{[1
]}

Wang, P ^{[1
]}

Wu, P ^{[1
]}

Xu, R ^{[1
]}

机构：

[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 05期

关键词：

D O I：

10.1016/j.bmcl.2003.12.027

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Development of structure-activity relationship of cyclic guanines I lead us to discovery of a potent and selective series of phosphodiesterase 5 inhibitors 52 59 (IC50 1.3-11.0 nM, PDE6/5 = 116-600). (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：1291 / 1294

页数：4

共 13 条

[1] Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity [J].

Ahn, HS ;

Bercovici, A ;

Boykow, G ;

Bronnenkant, A ;

Chackalamannil, S ;

Chow, J ;

Cleven, R ;

Cook, J ;

Czarniecki, M ;

Domalski, C ;

Fawzi, A ;

Green, M ;

Gundes, A ;

Ho, G ;

Laudicina, M ;

Lindo, N ;

Ma, K ;

Manna, M ;

McKittrick, B ;

Mirzai, B ;

Nechuta, T ;

Neustadt, B ;

Puchalski, C ;

Pula, K ;

Silverman, L ;

Smith, E ;

Stamford, A ;

Tedesco, RP ;

Tsai, HG ;

Tulshian, D ;

Vaccaro, H ;

Watkins, RW ;

Weng, XY ;

Witkowski, JT ;

Xia, Y ;

Zhang, HT .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (14) :2196-2210

[2] The discovery of novel, potent and selective PDE5 inhibitors [J].

Bi, YZ ;

Stoy, P ;

Adam, L ;

He, B ;

Krupinski, J ;

Normandin, D ;

Pongrac, R ;

Seliger, L ;

Watson, A ;

Macor, JE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) :2461-2464

[3]

BUNNAGE ME, Patent No. 9849166

[4] Cyclic GMP phosphodiesterase-5: Target of sildenafil [J].

Corbin, JD ;

Francis, SH .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (20) :13729-13732

[5]

Gresser U, 2002, EUR J MED RES, V7, P435

[6] Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors [J].

Ho, GD ;

Silverman, L ;

Bercovici, A ;

Puchalski, C ;

Tulshian, D ;

Xia, Y ;

Czarniecki, M ;

Green, M ;

Cleven, R ;

Zhang, HT ;

Fawzi, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (01) :7-12

[7] New aryl/heteroaryl C-N bond cross-coupling reactions via arylboronic acid cupric acetate arylation [J].

Lam, PYS ;

Clark, CG ;

Saubern, S ;

Adams, J ;

Winters, MP ;

Chan, DMT ;

Combs, A .

TETRAHEDRON LETTERS, 1998, 39 (19) :2941-2944

[8] ALPHA-TRIFLUOROMETHYLMETHYLENE AND ALPHA-TRIFLUOROMETHYLETHYLIDENE GAMMA-BUTYROLACTONES [J].

MAWSON, SD ;

WEAVERS, RT .

TETRAHEDRON LETTERS, 1993, 34 (19) :3139-3140

[9] Phosphodiesterase 5 inhibitors: Current status and potential applications [J].

Rotella, DP .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :674-682

[10] Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors [J].

Rotella, DP ;

Sun, Z ;

Zhu, YH ;

Krupinski, J ;

Pongrac, R ;

Seliger, L ;

Normandin, D ;

Macor, JE .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (26) :5037-5043

← 1 2 →